Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective study of nedaplatin-containing therapy in malignant gynecological tumors
ChiCTR2400083142Phase 4Not yet recruiting
- Sponsor
- Jingzhou First People's Hospital
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nedaplatin in ovarian cancer, fallopian tube cancer (PFTC), Cervical Cancer (CC) and 2 more, sponsored by Jingzhou First People's Hospital. Primary endpoints: Objective response rate, Duration of response and 2 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
nedaplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)Cervical Cancer (CC)endometrial cancer (EC)Gynecological neoplasia
Beyond the preview
Go deeper on ChiCTR2400083142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083142.